Genky DrugStores Co., Ltd. (9267) AI Stock Analysis

• Market Cap: ¥109.89B
• Dividend Yield: 0.36%
• Average Volume (3M): 73.45K
• Price to Earnings (P/E): 16.1
• Beta (1Y): 0.15
• Revenue Growth: 7.83%
• EPS Growth: 14.06%
• Country: JP
• Employees: 1,661
• Sector: Healthcare
• Sector Strength: 57
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 221.82
• Shares Outstanding: 30,996,967
• 10 Day Avg. Volume: 134,700
• 30 Day Avg. Volume: 73,446
• PEG Ratio: 1.15
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Genky DrugStores Co., Ltd. demonstrates strong financial health with robust revenue growth and profitability improvements. The upward technical trend supports a positive outlook, though overbought conditions warrant caution. Valuation metrics indicate a fair market price, while the high debt level remains a key risk factor.

Genky DrugStores Co., Ltd. Business Overview & Revenue Model

Company Description

Genky DrugStores Co., Ltd. (9267) is a prominent Japanese retail company operating in the drugstore sector. The company focuses on providing a wide range of products, including pharmaceuticals, health and beauty items, daily necessities, food, and beverages. With a strong presence across Japan, Genky DrugStores aims to cater to the daily needs of its customers by offering high-quality products at competitive prices.

How the Company Makes Money

Genky DrugStores Co., Ltd. generates revenue primarily through the sale of a diverse range of products in its retail stores. The company's revenue streams include the sale of pharmaceuticals, health and beauty products, and general merchandise such as food and household items. By leveraging its extensive network of physical stores, Genky DrugStores achieves scale and efficiency, enabling it to maintain competitive pricing. Additionally, the company may benefit from partnerships with suppliers and manufacturers, which can contribute to favorable purchasing terms and promotional opportunities. Overall, the company's earnings are driven by its ability to attract and retain customers through a comprehensive product offering and a convenient shopping experience.

Genky DrugStores Co., Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
184.86B	169.06B	154.64B	142.38B	123.60B
	Gross Profit
37.62B	34.55B	30.95B	30.29B	26.71B
	EBIT
9.02B	6.71B	5.68B	6.29B	4.34B
	EBITDA
14.47B	11.73B	10.73B	10.78B	7.86B
	Net Income Common Stockholders
6.32B	4.76B	4.42B	4.83B	2.76B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.90B	5.33B	5.44B	7.91B	6.62B
	Total Assets
113.94B	105.91B	97.12B	90.80B	83.15B
	Total Debt
30.65B	32.35B	30.96B	28.56B	30.39B
	Net Debt
24.75B	27.02B	25.52B	20.64B	23.77B
	Total Liabilities
67.26B	65.23B	60.88B	58.63B	55.46B
	Stockholders Equity
46.68B	40.68B	36.23B	32.17B	27.69B
Cash Flow		Free Cash Flow
2.81B	-1.16B	-4.43B	3.12B	-3.59B
	Operating Cash Flow
13.26B	8.77B	6.08B	12.08B	7.41B
	Investing Cash Flow
-10.63B	-9.74B	-10.59B	-8.83B	-11.22B
	Financing Cash Flow
-2.06B	854.00M	2.04B	-1.95B	7.99B

Genky DrugStores Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3580.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Positive. The current price of 3580 is above the 20-day moving average (MA) of 3083.35, above the 50-day MA of 2978.34, and above the 200-day MA of 3182.63, indicating a bullish trend. The MACD of 182.25 indicates Negative momentum. The RSI at 67.55 is Neutral, neither overbought nor oversold. The STOCH value of 88.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9267.

Genky DrugStores Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9989	78 Outperform	$549.07B	18.20	11.63%	2.67%	7.13%	7.29%
2875	76 Outperform	$950.09B	13.80	14.64%	1.74%	12.15%	44.46%
9267	75 Outperform	¥109.89B	16.14		0.36%	7.83%	14.06%
3349	75 Outperform	¥647.78B	19.51		0.68%	6.96%	-3.96%
7649	74 Outperform	$567.69B	21.22	10.45%	1.10%	17.94%	18.31%
3141	74 Outperform	¥525.82B	34.91		1.43%	5.56%	-43.53%
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%

Genky DrugStores Co., Ltd. Corporate Events

Genky DrugStores Reports Strong Financial Performance for Nine Months Ending March 2025

Genky DrugStores Co., Ltd. reported a 7.9% increase in net sales for the nine months ending March 20, 2025, compared to the same period the previous year. The company also saw a 9.4% rise in net income attributable to owners of the parent, reflecting strong operational performance. Despite a stock split implemented in June 2024, the company maintained its financial stability with a slight decrease in its equity ratio. The forecast for the fiscal year ending June 20, 2025, anticipates continued growth with a 9.3% increase in net sales and a 10.7% rise in net income, indicating positive momentum for stakeholders.

Genky DrugStores Updates February 2025 Sales Bulletin, Shows Positive Growth

Genky DrugStores Co., Ltd. issued a revised sales bulletin for February 2025, correcting previous inaccuracies. The updated report highlights a consistent growth in net sales and customer traffic across all and existing stores, alongside a strategic expansion with new store openings. This indicates a positive trajectory for the company’s operations and market positioning.